SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing significant selling pressure as investors react to a heavy capital expenditure forecast for AI infrastructure that has sharply compressed free cash flow. While the company's advertising business continues to show solid revenue growth, the community is debating whether these aggressive AI investments will deliver long-term returns or continue to weigh on margins.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending as investors digest a strong earnings report and the companys decision to maintain its capital expenditure forecast, which has successfully eased market anxieties regarding AI infrastructure spending. The community is actively debating the stock's role as a market stabilizer, with many highlighting Azure's cloud growth and Copilot adoption as key differentiators that distinguish Microsoft from other hyperscalers.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors debate whether the recent share price volatility represents a manipulation-driven pump-and-dump or a buying opportunity, given the company's QNX software integration in the automotive and robotics sectors. The community is actively tracking the upcoming August deadline for the Alloy Kore deal, while expressing intense frustration and suspicion over recent insider selling activity and management's silence during the current downward pressure.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following the broad regulatory approval of Anktiva in the UAE, which serves as a significant milestone for the company's global expansion strategy. The community is actively debating the potential for this news to catalyze a short squeeze, while also expressing frustration over the lack of broader institutional partnerships and recent stock volatility.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The market is experiencing heightened volatility fueled by persistent Middle East tensions, mixed earnings from tech giants, and intense community debate over the Fed's future rate path. Traders are actively monitoring bond yields and key support levels while debating whether recent price swings represent a bottom or a setup for further downside.

BlackBerry is seeing intense discussion around its QNX software platform serving as a critical foundational layer for physical AI and robotics, following high-profile partnerships with major semiconductor leaders. While the stock experiences volatility from insider trading activity and short interest, investors are primarily focused on the upcoming Alloy Kore contract announcements as a key catalyst for long-term revenue growth.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

Semiconductor stocks are facing intense volatility as traders debate whether recent price swings represent a healthy consolidation amid continued massive AI infrastructure spending or the start of a deeper sector-wide correction. While market sentiment remains conflicted due to geopolitical tensions and concerns over capital expenditure sustainability, the community is actively tracking support levels and debating the viability of leveraged ETFs in the face of ongoing sector rotation.

SharonAI Holdings, Inc. operates as a holding company that develops and delivers GPU cloud computing and AI solutions. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI Holdings is capturing investor interest following a major multi-year cloud computing agreement that has energized the community's focus on its infrastructure-heavy business model. Traders are actively debating the company's valuation, institutional backing from significant market players, and the potential for a long-term supply squeeze given its low-float status and expanding compute capacity.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is facing significant volatility ahead of a pivotal Advisory Committee meeting and a PDUFA deadline as investors debate whether the company's resubmitted BLA and long-term survival data can overcome historical FDA concerns regarding trial design and efficacy. The community is actively discussing the stock's high binary risk, questioning the validity of the data, and speculating on whether the company faces another complete response letter or a breakthrough approval.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is gaining traction as investors discuss its potential to capture significant market share in the brokerage sector, leading to active community debate regarding its valuation compared to industry peers. Market participants are closely watching technical levels and volume trends as bullish sentiment builds around recent platform enhancements and positive analyst updates.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

VKTX Stock Steady After-Hours On Positive Obesity Drug Pipeline Progress  

Equity

Viking has no approved drug products, and in the pre-revenue phase, investor attention centers almost entirely on clinical progress.

Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update PR Newswire SAN DIEGO, July 29, 2026 Conference call scheduled for 4:30 p.m. ET today-- Phase 3 VANQUISH 1...

How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q2 Results?

Novo Nordisk's Q2 results are set to spotlight Ozempic and Wegovy sales as oral launches and label expansions drive growth amid mounting competitive pressure.

Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?

Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results.

Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?

According to the average brokerage recommendation (ABR), one should invest in Viking Therapeutics (VKTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

LLY's Retatrutide Nears 2027 Filing With Two More Phase III Wins

Eli Lilly's retatrutide meets the primary endpoint in the phase III TRIUMPH-2 & TRIUMPH-3 studies, supporting planned regulatory submissions for obesity in 2027.

Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market

Viking Therapeutics, Inc. (VKTX) reached $35.39 at the closing of the latest trading day, reflecting a -5.15% change compared to its last close.

How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q2 Results?

LLY's blockbuster GLP-1 portfolio takes center stage as investors watch Mounjaro, Zepbound and Foundayo for clues to Q2 growth and outlook.

Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors

Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors PR Newswire SAN DIEGO,, July 23, 2026 Experienced Executive Brings Over Two Decades of Leadership Across Healthcare, Digital Health and CommercializationSAN DIEGO...

Missed AI, Memory Bull Run? Biotech May Be The Next Breakout Trade — But Retail Sentiment Has Never Been Lower 

Drugmakers have announced 37 biotech acquisitions worth at least $1 billion this year, topping the previous annual record.

$VKTX Q2 &#39;26 Earnings Results &amp; Recap

Reported GAAP EPS of -$1.10 down -89.66% YoY

Stocktwits

Viking Therapeutics Inc

 Q2 '26 Earnings Results & Recap

Reported GAAP EPS of -$1.10 down -89.66% YoY

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

$VKTX Q2 '26 Earnings Results & Recap

Reported GAAP EPS of -$1.10 down -89.66% YoY

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits Polls

Investors are eagerly anticipating the Q3 maintenance dosing data as a potential clinical validator for their obesity pipeline.

The stock remains a hotbed for M&A rumors, with persistent speculation that pharma giants are circling the high-value asset.

Tensions are running high as bulls challenge the massive short interest and accuse traders of manipulating price action via volume games.

Frustration is mounting among some shareholders regarding executive communication styles and persistent insider selling.

Current Price	$33.43
Prev Close	$33.86
Open	$33.86
Dividend Yield	0.00%
50-Day Moving Average	$33.86
Beta	1.63
Avg. Volume	2.77M
PE Ratio	-8.06

52-Week High	$43.15
52-Week Low	$22.96
Market Capitalization	$3.93B
EPS (Annual)	-$3.19
Price to Book	7.72
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

VKTXViking Therapeutics Inc

Latest VKTX News